208 results on '"Hiester, Andreas"'
Search Results
2. Phase 2 Single-arm Trial of Primary Retroperitoneal Lymph Node Dissection in Patients with Seminomatous Testicular Germ Cell Tumors with Clinical Stage IIA/B (PRIMETEST)
3. Minimally invasive retroperitoneal lymph node dissection for men with testis cancer: a retrospective cohort study of safety and feasibility
4. Definition and Impact on Oncologic Outcomes of Persistently Elevated Prostate-specific Antigen After Salvage Lymph Node Dissection for Node-only Recurrent Prostate Cancer After Radical Prostatectomy: Clinical Implications for Multimodal Therapy
5. Preoperative clinical and radiographic predictors of major vascular surgery in patients with testicular cancer undergoing post-chemotherapy residual tumor resection (PC-RPLND)
6. Late relapsing germ cell tumors with elevated tumor markers
7. Late toxicities and recurrences in patients with clinical stage I non-seminomatous germ cell tumours after 1 cycle of adjuvant bleomycin, etoposide and cisplatin versus primary retroperitoneal lymph node dissection – A 13-year follow-up analysis of a phase III trial cohort
8. Treatment of clinical stage I non-seminoma
9. Surgical treatment of metastatic germ cell cancer
10. Short-term and long-term outcomes after resection of thoracic growing teratoma syndrome
11. Long-term Outcomes of Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: Not as Good as Previously Thought
12. Adjunctive Surgery Is Often Without Oncological Benefit at Time of Postchemotherapy Retroperitoneal Lymph Node Dissection
13. Aktuelle Entwicklungen und Behandlungsmöglichkeiten für das Growing-Teratoma-Syndrom
14. Therapiemöglichkeiten des Seminoms im klinischen Stadium I und II unter Berücksichtigung der Langzeittoxizität
15. Management, Treatment, and Molecular Background of the Growing Teratoma Syndrome
16. Supplementary Table S4 from Detection of Recurrence through microRNA-371a-3p Serum Levels in a Follow-up of Stage I Testicular Germ Cell Tumors in the DRKS-00019223 Study
17. Supplementary Figure S1 from Detection of Recurrence through microRNA-371a-3p Serum Levels in a Follow-up of Stage I Testicular Germ Cell Tumors in the DRKS-00019223 Study
18. Data from Detection of Recurrence through microRNA-371a-3p Serum Levels in a Follow-up of Stage I Testicular Germ Cell Tumors in the DRKS-00019223 Study
19. Multiparametric Magnetic Resonance Imaging/Ultrasound Fusion Prostate Biopsy—Are 2 Biopsy Cores per Magnetic Resonance Imaging Lesion Required?
20. Risk Stratification of Equivocal Lesions on Multiparametric Magnetic Resonance Imaging of the Prostate
21. Oncological outcome of patients treated with spot-specific salvage lymphnode dissection (sLND) for positron-emission tomography (PET)-positive prostate cancer (PCa) relapse
22. Detection of recurrence through microRNA-371a-3p serum levels in a follow-up of stage I testicular germ cell tumors in the DRKS-00019223 study
23. Reply to Kirti Singh, Swarnendu Mandal, Manoj Kumar Das, Prasant Nayak, and Sambit Tripathy’s Letter to the Editor re: Andreas Hiester, Yue Che, Achim Lusch, et al. Phase 2 Single-arm Trial of Primary Retroperitoneal Lymph Node Dissection in Patients with Seminomatous Testicular Germ Cell Tumors with Clinical Stage IIA/B (PRIMETEST). Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.10.021
24. The management of stage I NSGCT
25. Relapse-free and overall survival in patients with non-seminomatous testicular germ cell tumours with teratoma-free primaries.
26. Prospective Evaluation of Magnetic Resonance Imaging Guided In-bore Prostate Biopsy versus Systematic Transrectal Ultrasound Guided Prostate Biopsy in Biopsy Naïve Men with Elevated Prostate Specific Antigen
27. Robotic Assisted Retroperitoneal Lymph Node Dissection for Small Volume Metastatic Testicular Cancer
28. PSA-basierte Prostatakarzinom-Früherkennung
29. Phase 2 Single-arm Trial of Primary Retroperitoneal Lymph Node Dissection in Patients with Seminomatous Testicular Germ Cell Tumors with Clinical Stage IIA/B (PRIMETEST)
30. Comparison of patient comfort between MR-guided in-bore and MRI/ultrasound fusion-guided prostate biopsies within a prospective randomized trial
31. The use of targeted MR-guided prostate biopsy reduces the risk of Gleason upgrading on radical prostatectomy
32. Combining PSA and PET features to select candidates for salvage lymph node dissection in recurrent prostate cancer
33. Need for organ preservation in postchemotherapy retroperitoneal lymph node dissection (PC-RPLND).
34. Single-course bleomycin, etoposide, and cisplatin (1xBEP) as adjuvant treatment in testicular nonseminoma clinical stage 1: outcome, safety, and risk factors for relapse in a population-based study
35. MP48-01 HOW TO OPTIMIZE PATIENT SELECTION BEFORE SALVAGE LYMPH NODE DISSECTION FOR NODAL RECURRENT PROSTATE CANCER: A NOVEL RISK STRATIFICATION TOOL
36. MR-sequences for prostate cancer diagnostics: validation based on the PI-RADS scoring system and targeted MR-guided in-bore biopsy
37. The PRIMETEST trial: Prospective phase II trial of primary retroperitoneal lymph node dissection (RPLND) in stage II A/B patients with seminoma.
38. Single-course bleomycin, etoposide, and cisplatin (1xBEP) as adjuvant treatment in testicular nonseminoma clinical stage 1: outcome, safety, and risk factors for relapse in a population-based study
39. Combining PSA and PET features to select candidates for salvage lymph node dissection in recurrent prostate cancer.
40. Preoperative clinical and radiographic predictors of major vascular surgery in patients with testicular cancer undergoing post-chemotherapy residual tumor resection (PC-RPLND)
41. Postchemotherapy Residual Tumor Resection in patients With Elevated Tumor Markers
42. Late relapsing germ cell tumors with elevated tumor markers
43. PD34-05 IMPACT OF PREVIOUS WHOLE PELVIS RADIATION THERAPY IN PATIENTS TREATED WITH SALVAGE LYMPH NODE DISSECTION FOR PROSTATE CANCER NODE-ONLY RECURRENCE: EVALUATION OF SURGICAL, PATHOLOGICAL, AND ONCOLOGICAL OUTCOMES
44. PD53-05 EJACULATION AFTER ROBOTIC RETROPERITONEAL LYMPH NODE DISSECTION STRATIFIED BY INDICATION, SURGICAL TEMPLATE, AND NERVE SPARING
45. Assessing the Best Surgical Template at Salvage Pelvic Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: When Can Bilateral Dissection be Omitted? Results from a Multi-institutional Series
46. Underestimation of Positron Emission Tomography/Computerized Tomography in Assessing Tumor Burden in Prostate Cancer Nodal Recurrence: Head-to-Head Comparison of Ga-68-PSMA and C-11-Choline in a Large, Multi-Institutional Series of Extended Salvage Lymph Node Dissections
47. Aktuelle Entwicklungen und Behandlungsmöglichkeiten für das Growing-Teratoma-Syndrom
48. Robotic Assisted Retroperitoneal Lymph Node Dissection for Small Volume Metastatic Testicular Cancer
49. Short-term and long-term outcomes after resection of thoracic growing teratoma syndrome
50. Therapiemöglichkeiten des Seminoms im klinischen Stadium I und II unter Berücksichtigung der Langzeittoxizität
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.